Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Glioblastoma 2Spondylitis, Ankylosing 1Signs and Symptoms 1Psoriasis 1Nutrition Disorders 1Lymphoma 1Leukemia, Myeloid, Acute 1Insulin Resistance 1Inflammatory Bowel Diseases 1Glioma 1Gastroparesis 1Feeding and Eating Disorders 1Esophageal Neoplasms 1Epilepsy 1Dumping Syndrome 1Diarrhea 1Colorectal Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Oxaliplatin 270Bevacizumab 260Fluorouracil 249Irinotecan 240Leucovorin 218Capecitabine 196Cetuximab 161Colonoscopy 74Folfox protocol 70Panitumumab 64regorafenib 62Drug Therapy 52Radiotherapy 50HMPL-013 50Blood Specimen Collection 45trifluridine tipiracil drug combination 43pembrolizumab 41Surveys and Questionnaires 35Standard of Care 35Nivolumab 34Neoadjuvant Therapy 34Surgical Procedures, Operative 33Magnetic Resonance Spectroscopy 31IFL protocol 27Trifluridine 26Interviews as Topic 26Celecoxib 26XELOX 25Early Intervention, Educational 24Specimen Handling 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Colorectal Neoplasms × Sulfasalazine × Clear all
NCT06134388 2023-11-18

Sulfasalazine in Patients With Metastatic Colorectal Cancer

Tanta University

Phase 3 Recruiting
50 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡